Pfizer Inc Archives - Lets Talk Health

Ranbaxy halts generic Lipitor production after recall: FDA

11/29/2012 majac Your Health Matters

(Reuters) – Indian generic drugmaker Ranbaxy Laboratories will stop manufacturing its version of Pfizer Inc’s cholesterol fighter, Lipitor, while it gets to the bottom of the cause of a recent recall, the U.S. Food and Drug Administration said on its website. Earlier this month, Ranbaxy recalled certain lots of the widely used cholesterol lowering medicine known generically as atorvastatin at doses of 10 milligrams, 20 mg and 40 mg after the company discovered contamination with tiny glass particles. …

Drug Administration, FDA, Pfizer Inc, Ranbaxy Laboratories

FDA warns against use of Pfizer’s Revatio in children

08/30/2012 majac Your Health Matters

(Reuters) – U.S. health regulators recommended against use of Pfizer Inc’s pulmonary arterial hypertension (PAH) drug Revatio in children up to 17 years of age, saying it had a higher risk of death when taken in a high dose. While the drug has never been approved for treatment of PAH in children, the U.S. Food and Drug Administration’s warning is against off-label use of the drug. …

Drug Administration, FDA, PAH, Pfizer Inc

Drugmaker Medivation posts loss as expenses jump

08/09/2012 majac Your Health Matters

(Reuters) – Drugmaker Medivation Inc returned to recording a quarterly loss after a rare first-quarter profit as expenses rose, sending its shares down 3 percent after market. April-June net loss narrowed to $5.5 million, or 15 cents per share, from $9.5 million, or 27 cents per share, a year earlier. Revenue, which Medivation generates mostly through collaborations with Astellas Pharma Inc, more than doubled to $42.9 million, boosted by $35.6 million of deferred revenue from ending a drug development deal with Pfizer Inc. …

April June, Astellas Pharma Inc, Drugmaker Medivation, Pfizer Inc

Deutsche cuts Biocon target price after Pfizer exit

03/13/2012 majac Your Health Matters

MUMBAI (Reuters) – Deutsche Bank cut its target price for Biocon Ltd shares by 9 percent to 215 rupees after Pfizer Inc ended a deal to sell insulin products made by the Indian drugmaker. “This issue raises its risk profile in this high-risk, capital-intensive business,” Deutsche Bank wrote in a research note. Biocon shares were trading at 253.75 rupees at 1.30 p.m. (0800 GMT), down 5.16 percent. The separation leaves India’s biggest biotech company without a partner to sell the insulin drugs in key global markets such as the United States. (Reporting by Abhishek Vishnoi; Editing by Ted Kerr)

Biocon Ltd, Deutsche Bank, India, Pfizer Inc

India’s Biocon to retain milestone payments from Pfizer deal

03/13/2012 majac Your Health Matters

MUMBAI (Reuters) – India’s Biocon Ltd will retain milestone payments it received from Pfizer Inc as part of a deal that allowed the U.S. drugmaker to sell Biocon’s insulin products globally, Biocon’s chairman said, without providing details. Certain additional payments would also come from Pfizer, Kiran Mazumdar Shaw told CNBC-TV18 on Tuesday. “This (additional) income will get reflected in our quarterly numbers,” she said, declining to give details. …

Kiran Mazumdar Shaw, Pfizer Inc

Pfizer cancer drug effect may be limited: FDA staff (Reuters)

12/05/2011 majac Your Health Matters

Reuters – Slower tumor growth in kidney cancer patients taking Pfizer Inc’s experimental drug, Inlyta, in a clinical trial was driven by a subset of patients who are rare in the United States, U.S. Food and Drug Administration researchers said.

Drug Administration, FDA, Pfizer Inc, United States

FDA staff find small subset behind Inlyta effect (Reuters)

12/05/2011 majac Your Health Matters

Reuters – Slower tumor growth in kidney cancer patients taking Pfizer Inc’s drug Inlyta in trial was driven by a small subset of patients who are likely rare in the United States, Food and Drug Administration researchers said.

Drug Administration, FDA, Pfizer Inc, United States